#1
Source: Journal of Clinical Oncology | Authors: Shah MA, Kennedy EB, et al. — ASCO Expert Panel, multi-institutional | Published: August 17, 2026
Score: 9/20 — Base 8 (Journal of Clinical Oncology) + 1 (biomarker-guided / precision — the update turns on HER2, PD-L1 and MSI-H/dMMR status as the selection axis) = 9. No study-type bonus: this is a living-guideline synthesis, not a primary randomised trial or meta-analysis. No clinical-impact bonus, because a guideline codifies evidence generated elsewhere rather than producing a new survival signal itself.
ASCO's living-guideline format exists so that a recommendation set can move when the evidence moves rather than on a fixed republication cycle, and version 2026.1.2 is that mechanism working as designed for advanced gastroesophageal cancer. The update addresses immunotherapy and targeted therapy across advanced gastroesophageal adenocarcinoma and squamous cell carcinoma, and its organising principle is biomarker-guided selection: HER2 status, PD-L1 expression, and MSI-H/dMMR status together determine which of several competing first-line platforms a patient should receive. That is a meaningfully different posture from the era when the question was simply whether to add a checkpoint inhibitor to chemotherapy. It is worth being clear about what this document is and is not — it is a synthesis authored by an ASCO Expert Panel, so it reports no new endpoint data of its own, and its value lies in adjudicating between trials rather than adding to them. For a busy clinic, the practical import is that the first-line conversation in gastroesophageal cancer now begins with a biomarker panel rather than a performance status, and the guideline is the current reference for how to sequence those results.
Post angle: The living guideline is doing what a static one cannot — moving when the evidence does. The real shift is that first line in gastroesophageal cancer now starts with a biomarker panel, not a chemotherapy backbone. #GIOnc #GastricCancer #EsophagealCancer
#2
Source: Clinical Cancer Research | Authors: Galy-Fauroux I, Asif-Laidin A, Evain M, … Zucman-Rossi J, Nault JC, Couty JP, Allaire M (senior) — Centre de Recherche des Cordeliers and multicentre France/Italy | Published: August 17, 2026
Score: 7/20 — Base 6 (Clinical Cancer Research) + 1 (biomarker-guided / precision — a candidate predictive marker for first-line atezolizumab-bevacizumab selection in HCC) = 7. No study-type bonus: this is a prospective translational immunophenotyping study with retrospective validation in existing trial cohorts, not an interventional trial. No clinical-impact bonus, because the signature is not yet prospectively validated as a treatment-selection tool.
Atezolizumab plus bevacizumab is the first-line standard in advanced hepatocellular carcinoma, and the field still has no reliable way to say in advance who will benefit. This study takes a prospective cohort of 31 patients starting first-line AtezoBev — 87% male, median age 65, 65% BCLC-C — and layers sequential PBMC immunophenotyping, cytokine profiling and whole-blood RNA sequencing across treatment. High baseline circulating γδ T cells were associated with disease control (p=0.006) and longer progression-free survival (p=0.02). In tumour RNA-sequencing, a high intratumoral γδ T signature tracked with higher response (p<0.01), longer progression-free survival (p<0.001) and longer overall survival (p=0.003) — and the critical control is that this held only in AtezoBev-treated patients, not in those given sorafenib, which is what separates a predictive marker from a merely prognostic one. Validation drew on GO30140/IMbrave150 (209 AtezoBev, 58 sorafenib) plus 163 MSI-high colorectal cancers treated with immunotherapy, where a high γδ T-cell signature again tracked with longer progression-free survival (p=0.034). On-treatment dynamics added a second axis: rising circulating CD8⁺TIGIT⁺ cells marked shorter progression-free survival (p=0.04) while rising CD8⁺PD-1⁺ cells marked longer (p=0.03), with paired transcriptomics confirming early induction of T-cell interferon-γ signalling by three weeks in responders. The cohort is small and the validation is retrospective, but the design asks the right question.
Post angle: A predictive biomarker has to fail in the comparator arm to earn the name. This γδ T-cell signature tracks response under atezolizumab-bevacizumab and does nothing under sorafenib — and it replicates in MSI-high CRC. Small cohort, right question. #HCC #GIOnc #Immunotherapy
-
Journal of Gastrointestinal Cancer — A narrative review of where first-line HER2-positive gastric and GEJ adenocarcinoma now stands: KEYNOTE-811 established pembrolizumab added to trastuzumab and chemotherapy, and phase III HERIZON-GEA-01 has since shown zanidatamab plus chemotherapy improves progression-free survival over trastuzumab plus chemotherapy, with zanidatamab plus tislelizumab and chemotherapy improving overall survival. Trastuzumab deruxtecan is moving earlier through platinum-free combinations. The question has shifted from whether to combine HER2 blockade with chemotherapy to which HER2 platform anchors first line.
-
Journal of Hepatology — Singal, Saborowski, Parikh and Banales survey liquid biomarkers across the full care continuum in hepatocellular carcinoma and biliary tract cancer: risk stratification, surveillance and early detection, treatment decisions and response monitoring. Their honest verdict is that cell-free DNA detection of actionable alterations has entered practice in select contexts, but most candidate markers still lack the prospective validation the enthusiasm assumes.
-
Gastroenterology (Editorial) — Pirzada and Ghany of the NIDDK Liver Diseases Branch argue that functional cure of hepatitis B does not reduce every patient to the same downstream hepatocellular carcinoma risk, and that surveillance after HBsAg loss should therefore be risk-stratified rather than uniform. An editorial, not a primary study.
-
Cancer Discovery (Research Watch) — A Cancer Discovery news brief reporting that a first-line HER2 antibody-drug conjugate combined with anti-PD-1 and chemotherapy showed efficacy in gastric cancer. Flagged here as a lead worth following rather than a result to act on: this is Research Watch commentary rather than a primary report, the AACR page returned HTTP 403 on attempted retrieval, and the underlying trial publication could not be identified — so no trial name and no endpoint figures are quoted.